News | August 06, 2024
UK Relonchem receives marketing authorization for Levonorgestrel 1.5 mg Tablets
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
The facility will have a capacity to manufacture upto 3 million tubes monthly
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
This registration enables companies to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Subscribe To Our Newsletter & Stay Updated
